Featured Research

from universities, journals, and other organizations

Soy sauce molecule may unlock drug therapy for HIV patients

Date:
May 5, 2014
Source:
University of Missouri-Columbia
Summary:
For HIV patients being treated with anti-AIDS medications, resistance to drug therapy regimens is commonplace. Often, patients develop resistance to first-line drug therapies, such as Tenofovir, and are forced to adopt more potent medications. Virologists now are testing the next generation of medications that stop HIV from spreading, and are using a molecule related to flavor enhancers found in soy sauce, to develop compounds that are more potent than Tenofovir.

Using a molecule found in soy sauce, Sarafianos and his team are developing compounds that are more potent than Tenofovir, one of the most-used HIV drugs.
Credit: Roger Meissen, Bond Life Sciences Center

For HIV patients being treated with anti-AIDS medications, resistance to drug therapy regimens is commonplace. Often, patients develop resistance to first-line drug therapies, such as Tenofovir, and are forced to adopt more potent medications. Virologists at the University of Missouri now are testing the next generation of medications that stop HIV from spreading, and are using a molecule related to flavor enhancers found in soy sauce, to develop compounds that are more potent than Tenofovir.

"Patients who are treated for HIV infections with Tenofovir, eventually develop resistance to the drugs that prevent an effective or successful defense against the virus," said Stefan Sarafianos, associate professor of molecular microbiology and immunology in the University of Missouri School of Medicine, and a virologist at the Bond Life Sciences Center at MU. "EFdA, the molecule we are studying, is less likely to cause resistance in HIV patients because it is more readily activated and is less quickly broken down by the body as similar existing drugs."

In 2001, a Japanese soy sauce company inadvertently discovered the EFdA molecule while trying to enhance the flavor of their product. The flavor enhancer is part of the family of compounds called "nucleoside analogues" which is very similar to existing drugs for the treatment of HIV and other viruses. EFdA samples were sent for further testing, which confirmed EFdA's potential usefulness against HIV and started more than a decade of research.

EFdA, along with eight existing HIV drugs, is part of the class of compounds called nucleoside reverse transcriptase inhibitors (NRTIs). NRTIs "hijack" the HIV replicating process by "tricking" building blocks inside the virus. Since EFdA appears similar to those building blocks, the virus is misled into using the imposter, which prevents HIV replication and halts the spread of the virus.

In their latest study, Sarafianos and his colleagues, including researchers from the University of Pittsburgh and the National Institutes of Health, helped define how EFdA works on a molecular level. Using virology techniques and nuclear magnetic resonance spectroscopy (NMR), they pieced together the exact structure and configuration of the molecule. Compounds developed by Sarafianos and his team currently are being tested for usefulness as potential HIV-halting drugs with pharmaceutical company Merck.

"The structure of this compound is very important because it is a lock-and-key kind of mechanism that can be recognized by the target," Sarafianos said. "EFdA works extremely well on HIV that is not resistant to anti-AIDS drugs, it also works even better on HIV that's become resistant to Tenofovir."

Grants from the National Institutes of Health funded this research which was published the journals Retrovirology, Antimicrobial Agents and Chemotherapy and The International Journal of Pharmaceutics.


Story Source:

The above story is based on materials provided by University of Missouri-Columbia. Note: Materials may be edited for content and length.


Journal References:

  1. Eleftherios Michailidis, Emily M Ryan, Atsuko Hachiya, Karen A Kirby, Bruno Marchand, Maxwell D Leslie, Andrew D Huber, Yee T Ong, Jacob C Jackson, Kamalendra Singh, Eiichi N Kodama, Hiroaki Mitsuya, Michael A Parniak, Stefan G Sarafianos. Hypersusceptibility mechanism of Tenofovir-resistant HIV to EFdA. Retrovirology, 2013; 10 (1): 65 DOI: 10.1186/1742-4690-10-65
  2. Wei Zhang, Michael A. Parniak, Stefan G. Sarafianos, Marilyn R. Cost, Lisa C. Rohan. Development of a vaginal delivery film containing EFdA, a novel anti-HIV nucleoside reverse transcriptase inhibitor. International Journal of Pharmaceutics, 2014; 461 (1-2): 203 DOI: 10.1016/j.ijpharm.2013.11.056
  3. K. A. Kirby, E. Michailidis, T. L. Fetterly, M. A. Steinbach, K. Singh, B. Marchand, M. D. Leslie, A. N. Hagedorn, E. N. Kodama, V. E. Marquez, S. H. Hughes, H. Mitsuya, M. A. Parniak, S. G. Sarafianos. Effects of Substitutions at the 4' and 2 Positions on the Bioactivity of 4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine. Antimicrobial Agents and Chemotherapy, 2013; 57 (12): 6254 DOI: 10.1128/AAC.01703-13

Cite This Page:

University of Missouri-Columbia. "Soy sauce molecule may unlock drug therapy for HIV patients." ScienceDaily. ScienceDaily, 5 May 2014. <www.sciencedaily.com/releases/2014/05/140505112542.htm>.
University of Missouri-Columbia. (2014, May 5). Soy sauce molecule may unlock drug therapy for HIV patients. ScienceDaily. Retrieved August 2, 2014 from www.sciencedaily.com/releases/2014/05/140505112542.htm
University of Missouri-Columbia. "Soy sauce molecule may unlock drug therapy for HIV patients." ScienceDaily. www.sciencedaily.com/releases/2014/05/140505112542.htm (accessed August 2, 2014).

Share This




More Health & Medicine News

Saturday, August 2, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Texas Quintuplets Head Home

Texas Quintuplets Head Home

Reuters - US Online Video (Aug. 1, 2014) After four months in the hospital, the first quintuplets to be born at Baylor University Medical Center head home. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
Ebola Patient Coming to U.S. for Treatment

Ebola Patient Coming to U.S. for Treatment

Reuters - US Online Video (Aug. 1, 2014) A U.S. aid worker infected with Ebola while working in West Africa will be treated in a high security ward at Emory University in Atlanta. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
Ebola Vaccine Might Be Coming, But Where's It Been?

Ebola Vaccine Might Be Coming, But Where's It Been?

Newsy (Aug. 1, 2014) Health officials are working to fast-track a vaccine — the West-African Ebola outbreak has killed more than 700. But why didn't we already have one? Video provided by Newsy
Powered by NewsLook.com
Study Links Certain Birth Control Pills To Breast Cancer

Study Links Certain Birth Control Pills To Breast Cancer

Newsy (Aug. 1, 2014) Previous studies have made the link between birth control and breast cancer, but the latest makes the link to high-estrogen oral contraceptives. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins